AZD-1390

AZD-1390

AZD-1390 is a novel, potent, and selective ATM kinase inhibitor developed by AstraZeneca. It is designed to enhance the efficacy of radiation therapy in the treatment of brain tumors.

Mechanism of Action

ATM kinase is a key protein involved in the repair of DNA damage, particularly double-strand breaks. Inhibition of ATM kinase by AZD-1390 prevents the repair of DNA damage caused by radiation therapy, thereby enhancing the cytotoxic effect of the therapy on tumor cells.

Clinical Trials

AZD-1390 has undergone Phase I clinical trials to evaluate its safety, tolerability, and preliminary efficacy in patients with brain tumors. The trials have shown promising results, with AZD-1390 demonstrating a favorable safety profile and potential for enhancing the efficacy of radiation therapy.

Potential Applications

While the primary focus of AZD-1390 development has been on the treatment of brain tumors, its mechanism of action suggests potential applications in the treatment of other types of cancer as well. By inhibiting DNA repair, AZD-1390 could potentially enhance the efficacy of other DNA-damaging treatments, such as chemotherapy.

Future Directions

Further clinical trials are needed to fully evaluate the efficacy and safety of AZD-1390 in patients with brain tumors and other types of cancer. In addition, research is ongoing to better understand the role of ATM kinase in DNA repair and how its inhibition can be leveraged to improve cancer treatment outcomes.